Technology
Sequencing by expansion (SBX) technology
Overcoming limitations of today’s next-generation sequencing (NGS) technologies
As Roche Sequencing Solutions looks forward to meeting tomorrow’s biggest needs in genomics, it’s clear that today’s sequencing technologies face several limitations that impact growing needs for faster speed, improved accuracy, greater scalability, and increased flexibility.
Some traditional sequencing technologies leverage a cycle-based approach for measuring the bases of the DNA, which delays access to usable data. While on-market single-molecule nanopore technology addresses this challenge, it can be limited by fundamental signal-to-noise limitations—a result of poor spatial resolution and molecular distinction of nucleobases.
The SBX technology is in development and not commercially available. The content of this material reflects current study results or design goals.
Find out how SBX is paving the way for new opportunities in multi-omics research
Learn how Mark Korkoris and his team are transforming what’s possible with expanded applications and improved performance using sequencing by expansion.
A new GUINNESS WORLD RECORDS™ title has been set
for the fastest DNA sequencing technique, in collaboration with Broad Clinical Labs and Boston Children’s Hospital. Find out how we did it in a brand-new publication in the NEJM.
A new approach to NGS
Roche has responded to the demand for improved performance by developing a new category of NGS technology, called sequencing by expansion (SBX). This powerful approach to NGS has been designed for flexibility and performance, with headroom to scale into the future. Specifically, SBX boasts several advantages, including:
- Flexible operation that is tunable to sample needs
- High accuracy with demonstrated F1 scores of >99.80% (SNV) and >99.7% (InDel) for HG001 whole genome samples
- Very high throughput capable of 7 genomes in 1 hour at >30x; >5B duplex reads in 1 hour of sequencing
- Flexible read lengths spanning 50bp to >1000bp
- Ultra-fast workflow options for urgent samples, including sample to variant call format (VCF) in <5 hours
- Cost efficiency enabled by a scalable and reusable sensor module
Fundamentally, SBX technology converts DNA information into a longer, “expanded” molecule, overcoming the spatial challenges of current nanopore technology and enabling higher signal-to-noise for improved accuracy. This expanded molecule, or Xpandomer, is then fed through Roche’s proprietary nanopore, driving single-molecule sequencing at incredibly high rates of speed and facilitating rapid access to usable sequencing data.
The SBX technology is in development and not commercially available. The content of this material reflects current study results or design goals.
- ASHG materials
- ESHG materials
- AGBT materials
ASHG 2025 Workshop Videos
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Event posters
Demonstrating the versatility, accuracy and throughput of Sequencing By Expansion (SBX)
Enhanced Detection of Structural Variants, VNTRs, and Haplotype Phasing with SBX Simplex Longer Sequencing (SBX-SL)
Whole Genome Precision at Scale: Sequencing by Expansion for Cancer Genomics Research
Whole Genome Sequencing Minimum Residual Disease Detection using Sequencing By Expansion (SBX)
ESHG workshop resources
Engineered for both quality and efficiency, SBX offers high-accuracy whole-genome sequencing (WGS) through its duplex sequencing method, SBX-D. This innovative approach links both strands of the target DNA within a single read.
Utilizing SBX-D, seven genome in a bottle (GIAB) reference samples can be sequenced at over 30X coverage in less than one hour, achieving impressive F1 scores of greater than 99.8% for single nucleotide variants (SNVs) and greater than 99.7% for insertions and deletions (Indels). This presentation further details the high-sensitivity variant calling performance of SBX-D using paired tumor/normal formalin-fixed paraffin-embedded (FFPE) samples. Additionally, data was presented from a 15-sample, tissue-aware Minimal Residual Disease (MRD) study, demonstrating the detection of MRD at levels as low as 1x10⁻⁶ tumor fraction. Furthermore, the utility of longer (~1000mer) SBX-simplex reads, which offer a throughput of 1 Tb per sequencing hour, is also discussed. Watch this presentation to discover more about Roche’s novel SBX technology and its remarkable potential.
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Sequencing by Expansion (SBX): A versatile, high throughput single molecule sequencing technology
Mark Kokoris
Head, SBX Technology
Roche Diagnostics Solutions
Sean Hofherr, PhD @ESHG25
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Refining the SBX Fast workflow for reproducible speed and performance
Sean Hofherr, PhD, FACMG
Chief of Clinical Strategy and Product Development
Broad Clinical Labs
Redefining nanopore sequencing with Duplex Sequencing by Expansion (SBX-D)
A high-accuracy, high-throughput sequencing technology
SBX sequencing as a flexible RNA-seq toolkit
Enabling high throughput single cell transcriptomic profiling at scale
AGBT workshop presentations
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
SBX Technology
Mark Kokoris
Head, SBX Technology
Roche Diagnostics Solutions
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Cancer Whole Genome Sequencing using SBX technology
Edwin Cuppen
Scientific director
Hartwig Medical Foundation
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Enabling Rapid WGS for Trios by Roche SBX Technology
Sean Hofherr, PhD, FACMG
Chief of Clinical Strategy and Product Development
Broad Clinical Labs
Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.
Multiomic drug response profiling in highly multiplexed cancer cell lines
Aziz Al'Khafaji, PhD
Director, Molecular R&D
PI, Methods Development Lab
Broad Clinical Labs
The SBX technology is in development and not commercially available. The content of this material reflects current study results or design goals.
Stay up to date
Sign up to stay current on the latest advancements in SBX technology.